Overview

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

Status:
Completed
Trial end date:
2017-09-28
Target enrollment:
Participant gender:
Summary
This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.
Phase:
Phase 2
Details
Lead Sponsor:
Chase Pharmaceuticals Corporation
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Treatments:
Donepezil
Solifenacin Succinate